Cargando…

Bacillus subtilis in PVA Microparticles for Treating Open Wounds

[Image: see text] Open wound dressings should provide a moist environment, protect the wound from bacterial contamination, and shield it from further damage. These requirements, however, are hard to accomplish since such wounds are colonized by pathogenic bacteria, including resistant species such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben David, Noa, Mafi, Mahsa, Nyska, Abraham, Gross, Adi, Greiner, Andreas, Mizrahi, Boaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173545/
https://www.ncbi.nlm.nih.gov/pubmed/34095658
http://dx.doi.org/10.1021/acsomega.1c00790
_version_ 1783702742623059968
author Ben David, Noa
Mafi, Mahsa
Nyska, Abraham
Gross, Adi
Greiner, Andreas
Mizrahi, Boaz
author_facet Ben David, Noa
Mafi, Mahsa
Nyska, Abraham
Gross, Adi
Greiner, Andreas
Mizrahi, Boaz
author_sort Ben David, Noa
collection PubMed
description [Image: see text] Open wound dressings should provide a moist environment, protect the wound from bacterial contamination, and shield it from further damage. These requirements, however, are hard to accomplish since such wounds are colonized by pathogenic bacteria, including resistant species such as methicillin-resistant Staphylococcus aureus (MRSA). A new approach for treating open wounds that is based on sticky and dissolvable polyvinyl alcohol (PVA) microparticles containing live Bacillus subtilis (B. subtilis) is described. Microparticles, fabricated by the spray-drying technique, were administered directly to an open wound while B. subtilis continuously produced and secreted antimicrobial molecules. B. subtilis in PVA microparticles demonstrated remarkable antibacterial activity against MRSA and S. aureus. In in vivo experiments, both B. subtilis and empty PVA microparticles were effective in decreasing healing time; however, B. subtilis microparticles were more effective during the first week. There was no evidence of skin irritation, infection, or other adverse effects during the 15 day postoperative observation period. This concept of combining live secreting bacteria within a supportive delivery system shows great promise as a therapeutic agent for open wounds and other infectious skin disorders.
format Online
Article
Text
id pubmed-8173545
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-81735452021-06-04 Bacillus subtilis in PVA Microparticles for Treating Open Wounds Ben David, Noa Mafi, Mahsa Nyska, Abraham Gross, Adi Greiner, Andreas Mizrahi, Boaz ACS Omega [Image: see text] Open wound dressings should provide a moist environment, protect the wound from bacterial contamination, and shield it from further damage. These requirements, however, are hard to accomplish since such wounds are colonized by pathogenic bacteria, including resistant species such as methicillin-resistant Staphylococcus aureus (MRSA). A new approach for treating open wounds that is based on sticky and dissolvable polyvinyl alcohol (PVA) microparticles containing live Bacillus subtilis (B. subtilis) is described. Microparticles, fabricated by the spray-drying technique, were administered directly to an open wound while B. subtilis continuously produced and secreted antimicrobial molecules. B. subtilis in PVA microparticles demonstrated remarkable antibacterial activity against MRSA and S. aureus. In in vivo experiments, both B. subtilis and empty PVA microparticles were effective in decreasing healing time; however, B. subtilis microparticles were more effective during the first week. There was no evidence of skin irritation, infection, or other adverse effects during the 15 day postoperative observation period. This concept of combining live secreting bacteria within a supportive delivery system shows great promise as a therapeutic agent for open wounds and other infectious skin disorders. American Chemical Society 2021-05-20 /pmc/articles/PMC8173545/ /pubmed/34095658 http://dx.doi.org/10.1021/acsomega.1c00790 Text en © 2021 The Authors. Published by American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Ben David, Noa
Mafi, Mahsa
Nyska, Abraham
Gross, Adi
Greiner, Andreas
Mizrahi, Boaz
Bacillus subtilis in PVA Microparticles for Treating Open Wounds
title Bacillus subtilis in PVA Microparticles for Treating Open Wounds
title_full Bacillus subtilis in PVA Microparticles for Treating Open Wounds
title_fullStr Bacillus subtilis in PVA Microparticles for Treating Open Wounds
title_full_unstemmed Bacillus subtilis in PVA Microparticles for Treating Open Wounds
title_short Bacillus subtilis in PVA Microparticles for Treating Open Wounds
title_sort bacillus subtilis in pva microparticles for treating open wounds
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173545/
https://www.ncbi.nlm.nih.gov/pubmed/34095658
http://dx.doi.org/10.1021/acsomega.1c00790
work_keys_str_mv AT bendavidnoa bacillussubtilisinpvamicroparticlesfortreatingopenwounds
AT mafimahsa bacillussubtilisinpvamicroparticlesfortreatingopenwounds
AT nyskaabraham bacillussubtilisinpvamicroparticlesfortreatingopenwounds
AT grossadi bacillussubtilisinpvamicroparticlesfortreatingopenwounds
AT greinerandreas bacillussubtilisinpvamicroparticlesfortreatingopenwounds
AT mizrahiboaz bacillussubtilisinpvamicroparticlesfortreatingopenwounds